Filing Flows › Karyopharm Therapeutics (KPTI) › Next earnings date
Karyopharm Therapeutics (KPTI) earnings on Nov 12, 2026: what to expect
Karyopharm Therapeutics (KPTI) is expected to report earnings on Nov 12, 2026 (estimated), in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$1.31 (−$1.37 to −$1.26, 2 estimates) on revenue of $33.5M, against −$3.82 and $44.0M a year ago. It beat the EPS estimate in 25% of the quarters on record; Filing Flows' model gives it a 50% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$3.82 on revenue of $46.3M, against the analysts' −$1.31.
The last report
Karyopharm Therapeutics reported revenue of $33.4M for the second quarter 2026 (-12% Y/Y), net loss $67.0M: Product $30.8M, License and Other $2.7M. How it makes money → · Every quarter →
Karyopharm Therapeutics' latest quarter
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
Questions
When does KPTI report earnings?
Karyopharm Therapeutics is expected to report on Nov 12, 2026 (estimated).
What are analysts expecting from Karyopharm Therapeutics?
EPS of −$1.31 and revenue of $33.5M for the quarter.
Does Karyopharm Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 25% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.